Published on in Vol 7, No 5 (2021): May

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/27609, first published .
Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome

Journals

  1. Vulturar D, Neag M, Vesa Ș, Maierean A, Gherman D, Buzoianu A, Orăsan O, Todea D. Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection. International Journal of Molecular Sciences 2022;23(22):14462 View
  2. Edinoff A, Alpaugh E, Newgaard O, Wajid I, Klapper R, Cornett E, Kaye A, Iyer P, Kaye A. Tocilizumab for Severe COVID-19 Infection and Multisystem Inflammatory Syndrome in Adults and Children. Life 2023;13(4):889 View
  3. Al-Mistarehi A, El-Akawi S, Kheirallah K, Bani Ata E, Zaitoun K, Khassawneh A, Jarrah A, Alzoubi H, Al-Azzam S, Karasneh R, Altawalbeh R, Khassawneh B. Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study. Cureus 2024 View
  4. Luo Q, Zheng Y, Zhang J. Combination Therapies against COVID-19. Frontiers in Bioscience-Landmark 2022;27(9) View